Fennec Pharmaceuticals Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $362.9M
- Price
- $10.35
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.54%
- Volume
- 99.1K
About
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Quick stats
Shares outstanding35.1M
Computed float22.1M
Float / shares63.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001211583
Websitehttps://www.fennecpharma.com
AI Summary
AI-generated1/24
standardbullishclinical trial
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals presented detailed results from the investigator-initiated Phase 2 STS-J01 study of PEDMARK in Japan at the SIOP 2026 annual meeting, with ASHA-defined hearing loss in 24.0% of patients versus a prespecified historical benchmark of 56.4% (P=0.001).
By Brock criteria, 84.0% of patients had Grade 0 hearing loss and no Grade 3 or 4 hearing loss was observed, while objective tumor responses appeared in 23 of 24 evaluable patients (95.8%) — making STS-J01 the third study to show PEDMARK does not interfere with cisplatin antitumor activity, with pharmacokinetic data supporting the six-hour dosing interval.
Fennec is pursuing registration in Japan and exploring partnering or licensing opportunities for PEDMARK, so the data strengthen the case for a future regional deal and commercial entry.
Red flags
- Single-arm, open-label Phase 2 with a 25-patient efficacy population; comparison is against a historical benchmark rather than a randomized control
- Japan commercialization is not yet de-risked — registration is still pending and no regional partner or licensee has been secured